These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 23189411

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adding telaprevir improves cure rate in patient with HCV infection.
    AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
    [No Abstract] [Full Text] [Related]

  • 5. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R, Fagiuoli S, Sacchi P.
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract] [Full Text] [Related]

  • 6. Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Foster GR, Serfaty LD.
    Liver Int; 2012 Feb; 32 Suppl 1():61-3. PubMed ID: 22212574
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
    García-Toro M, Vilella Martorell A, Carral Martínez M, Jimeno Beltrán T, Román Ruiz del Moral Y, Pradas Guerrero C, Gili Planas M, Roca Bennasar M.
    Gastroenterol Hepatol; 2011 Apr; 34(4):307-8. PubMed ID: 21376422
    [No Abstract] [Full Text] [Related]

  • 11. Retreatment of hepatitis C patients who do not respond to interferon: the search continues.
    Pianko S, McHutchison J.
    Am J Gastroenterol; 2000 May; 95(5):1122-4. PubMed ID: 10811315
    [No Abstract] [Full Text] [Related]

  • 12. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC, Gogălniceanu P, Mihai C.
    Rev Med Chir Soc Med Nat Iasi; 2014 May; 118(2):272-8. PubMed ID: 25076687
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutics: new drugs hit the target.
    Schlütter J.
    Nature; 2011 Jun 08; 474(7350):S5-7. PubMed ID: 21666733
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
    AIDS Treat News; 2002 Oct 18; (384):5. PubMed ID: 12434764
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hepatitis C: new treatment overview.
    Stoia J.
    AIDS Treat News; 1998 Sep 04; (302):5-6. PubMed ID: 11365763
    [Abstract] [Full Text] [Related]

  • 19. [PEG-interferon alfa 2a against hepatitis C. Better as the standard therapy].
    MMW Fortschr Med; 2001 Nov 01; 143(44):58. PubMed ID: 11732405
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.